Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis

American Journal of Managed Care

Volumn 4, Issue 10, 1998, Pages 1377-1382

  Ettinger, Bruce ^a   Pressman, Alice ^a   Schein, Jeffrey ^b  

^a KAISER PERMANENTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ARTICLE; CONSULTATION; DATA ANALYSIS; DRUG CHOICE; FEMALE; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MEDICAL RECORD; OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT PLANNING;

AGED; ALENDRONATE; CALIFORNIA; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INCIDENCE; MIDDLE AGED; OFFICE VISITS; OSTEOPOROSIS; PATIENT ADMISSION; RETROSPECTIVE STUDIES;

EID: 0031733852     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Man Care Pharm (in press).
2. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-1443.
3. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC II. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101:488-501.
4. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541.
5. Levin TR, Schmittdiel JA, Kunz K, et al. Costs of acid-related disorders to a health maintenance organization. Am J Med 1997;103:520-528.
6. Nightingale SL. From the Food and Drug Administration. JAMA 1996;275:1534.
7. SAS Institute. SAS User's Guide: Statistics, Version 6. Cary, NC: SAS Institute, Inc.; 1991.
8. Facts and Comparisons. St. Louis, MO: JB Lippincott; 1991: 1059.
9. Drugs Used in Disorders of the Upper Gastrointestinal Trad. AMA Drug Evaluations. Chicago, III: American Medical Association; 1991: II/GI-1.
10. Elliott SN, McKnight W, Davies NM, MacNaughton WK, Wallace JL. Alendronate induces gastric injury and delays ulcer healing in rodents. Life Sci 1998;62:77-91.
11. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population. Br Med J 1995;311:293-295.